Sensus Healthcare (NASDAQ:SRTS) was downgraded by equities research analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Wednesday, TheStreetRatingsTable reports.

SRTS has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Sensus Healthcare in a report on Monday, May 13th. Northland Securities downgraded Sensus Healthcare from a “market perform” rating to an “under perform” rating in a report on Tuesday, January 29th. Alliance Global Partners downgraded Sensus Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Roth Capital reissued a “buy” rating on shares of Sensus Healthcare in a report on Tuesday, February 19th. Finally, Maxim Group reissued a “buy” rating and issued a $11.00 target price on shares of Sensus Healthcare in a report on Friday, May 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $10.32.

NASDAQ SRTS opened at $5.53 on Wednesday. Sensus Healthcare has a twelve month low of $5.22 and a twelve month high of $9.23. The company has a market cap of $94.32 million, a P/E ratio of -39.50 and a beta of -0.53.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.11). Sensus Healthcare had a negative net margin of 11.65% and a negative return on equity of 13.34%. The firm had revenue of $5.44 million for the quarter, compared to the consensus estimate of $7.81 million. On average, research analysts predict that Sensus Healthcare will post -0.13 EPS for the current fiscal year.

In other Sensus Healthcare news, EVP Richard Golin sold 5,943 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $7.56, for a total value of $44,929.08. Following the sale, the executive vice president now directly owns 925,237 shares of the company’s stock, valued at $6,994,791.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 7,203 shares of company stock worth $54,379 over the last three months. Corporate insiders own 31.20% of the company’s stock.

Several large investors have recently made changes to their positions in SRTS. Renaissance Technologies LLC lifted its holdings in shares of Sensus Healthcare by 75.0% during the third quarter. Renaissance Technologies LLC now owns 48,100 shares of the company’s stock valued at $403,000 after purchasing an additional 20,612 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sensus Healthcare by 48.2% during the third quarter. Vanguard Group Inc. now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares in the last quarter. Vanguard Group Inc lifted its holdings in shares of Sensus Healthcare by 48.2% during the third quarter. Vanguard Group Inc now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Sensus Healthcare by 10.2% during the fourth quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock valued at $192,000 after purchasing an additional 2,418 shares in the last quarter. Finally, Northern Trust Corp bought a new position in shares of Sensus Healthcare during the fourth quarter valued at $86,000. 8.97% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading: What is an investor looking for in an SEC filing?

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.